Introduction
The human genome contains a variety of retrovirus-like elements called 'human endogenous retroviruses' (HERVs). HERVs probably represent remnants of ancient germ line infections of exogenous retroviruses which have been transmitted as stable Mendelian genes through the germ line (for review see Refs 1 and 2) . Their biological function is unknown, but like other transposable elements they may have contributed to shape the eucaryotic genome. [1] [2] [3] [4] [5] On the other hand, these retroelements are believed to represent possible pathogenic agents in carcinogenesis, where they could act by insertional mutagenesis or involvement in chromosomal aberrations. 6, 7 To limit its potential effects on genetic stability, HERV expression is repressed by different host mechanisms in normal cells, including silencing of active elements by CpG methylation. [8] [9] [10] The human endogenous retrovirus type K (HERV-K), initially characterized by its homology with MMTV ('murine mammary tumor virus'), comprises 30-50 full-length members per haploid genome and 10 000 to 25 000 solitary long terminal repeats (LTRs). 1, 2, 11 Whereas almost all HERVs are defective on account of multiple nonsense mutations and deletions, members of the HERV-K family often harbor intact open reading frames for the gag, pol or env genes. 1, 2 Nevertheless, recent data suggest that the human genome does not contain an entire, intact proviral copy of HERV-K. 12 Among the different products potentially encoded by HERV- K sequences, an 80 kDa protein related to Gag polyprotein has been identified in teratocarcinoma cell lines and in human germ cell tumors. 13 Interestingly, the high expression of HERV-K observed in these cells is associated with the presence of antibodies directed against its retroviral products in patients with germ cell tumors. 13, 14 HERV-K expression may be involved in malignancies other than germ cell tumors, such as hematological diseases. Observations have suggested that this may be the case in essential thrombocythemia 15 and in leukemias. 16, 17 However, the differences in HERV-K expression between normal and leukemic blood cells remain to be defined. It seems the clonal amplification of HERV-K transcripts in leukocytes from leukemia patients initially observed 16 was not confirmed in later studies, except in chronic myelogenous leukemia in blast crisis. 18 Nevertheless, antibody response against HERV-K peptides reported in leukemia patients suggests that members of the HERV-K family may be overexpressed in leukemic cells. 19 In this study, we report different transcriptional expression levels of HERV-K10-like sequences -also called HML-2 (human MMTV-like, group 2) -in normal and leukemic white blood cells. Using real-time quantitative RT-PCR (Taqman), we showed that these sequences were overexpressed in different leukemia samples, enough so to be detected by Northern blot. Furthermore, there was no significant variation of HERV-K expression in normal peripheral blood mononuclear cells (PBMCs) after exposure to different factors potentially modulating HERV expression, suggesting that HERV-K overexpression in leukemia samples might be specifically associated with tumor development.
Materials and methods

Patient characteristics and cell preparation
The experimental group consisted of three patients with B chronic lymphoid leukemia (CLL Nos 1-3); two with chronic myelogenous leukemia (CML Nos 1 and 2); two with acute myelogenous leukemia (AML Nos 1 and 2), and one with acute lymphoid leukemia (ALL). CLL1 was a 37-year-old man diagnosed in October 1998 at stage B according to the Binet classification, who had never been treated, with 60 000 lymphocytes per mm 3 . CLL2 was a 53-year-old woman diagnosed in January 1996 at stage C according to the Binet classification, who had never been treated, with 110 000 lymphocytes per mm 3 . CLL3 was a 77-year-old man diagnosed in 1993 at stage C according to the Binet classification, who had previously been treated with chlorambucil, with 51 000 lymphocytes per mm 3 . CML1 was a 58-year-old woman diagnosed as chronic phase CML in 1994 and studied after myeloid blastic transformation, treated by hydroxyurea, with 30 000 white blood cells (WBC) per mm 3 (2% blasts). CML2 was a 59-year-old woman diagnosed as chronic phase CML in 1992 and also studied after a myeloid blastic transformation, treated by hydroxyurea, with 2400 WBC/mm 3 (50% blasts). AML1 was a 61-year-old man diagnosed as AML (M-5) in March 2000, that is, at the time of the study, with 56 000 WBC/mm 3 (20% blasts). AML2 was a 76-year-old man diagnosed as having a myelodysplasic syndrome in February 1998, at AML stage in April 2000, who had never been treated, with 5900 WBC/mm 3 (83% blasts). ALL was a 54-year-old man diagnosed as pro-B ALL in April 2000, with 4000 WBC/mm 3 (40% blasts). Umbilical cord blood was obtained by aspiration after cesarian delivery at full term from a pregnant woman from whom informed consent was obtained.
Mononuclear cells were separated by using Ficoll-Paque (Amersham, Bucks, UK) density gradient centrifugation. Healthy PBMCs were collected from five different normal individuals using the same method.
Cell culture
The human teratocarcinoma cell line Tera-1 (American Type Culture Collection, Rockville, MD, USA; ref. HTB 105) was maintained at 37°C (CO 2 5%, H 2 O 95%) in MacCoy's culture medium supplemented with 10% fetal calf serum and 2 mM glutamine. The cells were split weekly after trypsinization in a 1/3 ratio, with one change of medium after 3 days.
Healthy PBMC treatment with exogenous agents
PHA stimulation: 10 7 control PBMCs were grown in RPMI 1640 medium supplemented with 10% fetal calf serum, 2 mM glutamine, 1 mM sodium pyruvate and antibiotics; treated cells were maintained in the same medium with 10 g/ml PHA for 3 days. Proliferation was checked with the 3 Hthymidine incorporation method.
Exposure to 5-azacytidine (AZC):
10 7 control PBMCs were grown in supplemented RPMI 1640 medium with 0.1% ethanol; 10 7 treated cells were grown in the same medium with AZC 10 M in 0.1% ethanol. 3 × 10 6 cells were collected at 0, 24 and 48 h.
Gamma irradiation:
After gamma irradiation at 10 or 25 Gy, 1.5 × 10 7 cells were grown in supplemented RPMI 1640 medium and collected at 1, 3, 18, 48 and 96 h. An identical number of non-irradiated cells was maintained in the same culture conditions as controls.
RNA purification and reverse transcription
Total RNA was extracted using 'Rneasy mini or midi columns' kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. To prevent contamination with genomic DNA, total RNA was subsequently treated with 10 IU RNase free-DNase I (Boehringer, Mannheim, Germany) and 15 IU Rnase inhibitor (Pharmacia, Uppsala, Sweden) at 37°C for 30 min in 100 mM sodium acetate (pH 5.0, 5 mM MgSO 4 ), followed by phenol/chloroform extraction. Two g of treated RNA were used in a cDNA first strand synthesis which was primed by random hexanucleotides using (final amounts or concentrations): 300 IU M-MuLV reverse transcriptase (GibcoLeukemia BRL, USA), 60 IU Rnase inhibitor (Pharmacia), 0.5 mmol/l each deoxynucleotide triphosphate (Pharmacia), 5 mmol/l DTT and 1 mol/l hexanucleotides (Pharmacia). The mixture was incubated at 42°C for 45 min.
Qualitative RT-PCR
Approximately 100 ng cDNA were amplified in a 50 l total volume reaction containing 2.5 IU ampli-Taq Gold DNA polymerase (Applied Biosystem, USA), 1.25 mmol/l MgCl 2 and 10 pmol of specific HERV-K10 primers (H1S: 5Ј-GGG TGA TAA TGG GGC AAA CTA AA-3Ј, H3R: 5Ј-GAC CTG CTG GAA GAG GAC TTG T-3Ј) or specific porphobilinogen desaminase (PBGD) primers (PBGDs: 5Ј-CTG GTA ACG GCA ATG CGG CT-3Ј; PBGDas: 5Ј-GCA GAT GGC TCC GAT GGT GA-3Ј). Amplification was performed using a 94°C 12 min denaturation step, followed by 35 cycles of 45 s denaturation at 94°C, 45 s at 58°C (H1S-H3R) or 56°C (PBGDs-PBGDas) for primer annealing and 45 s at 72°C for polymerization. Final amplification included a polymerization step at 72°C for 7 min. A 570 bp HERV-K or a 436 bp PBGD amplification product was visualized after electrophoresis in 1% agarose gels by ethidium bromide staining.
Quality of retrotranscription was controlled for each sample by PBGD PCR, primers of which overlap two adjacent exons. Furthermore, in order to confirm that there was no DNA genomic contamination, control PCR was performed with RNA before reverse transcription using H1S and H3R HERV-K10 primers.
Quantitative RT-PCR
Real-time quantitative RT-PCR was performed using the TaqMan PCR core reagents (Applied Biosystem) according to the manufacturer's recommendations. Specific primers and probe were determined using the 'Primer Express 1.0' software (Applied Biosystem). Their HERV-K10 specificity was assessed after sequence alignment using the Blast data bank. Briefly, 60 ng cDNA were amplified in a 50 l total volume reaction containing: 1.25 IU ampli-Taq Gold DNA polymerase (Applied Biosystem), 5.5 mmol/l MgCl 2 , 50 nmol/l each HERV-K10 specific primer (HERV-K10s: 5Ј-AGA GTC TAA ACC ACG AGG CAC AA-3Ј; HERV-K10as: 5Ј-TTC TTT AAC CTG CTT TTG AGG TTG T-3Ј), 50 nmol/l each 18S ribosomal RNA primer (Applied Biosystem), 50 nmol/l HERV-K10 specific probe (5Ј-(Fam)CCT CTT CCA GCA GGT CAG GTC CTC G (Tamra)-3Ј) (Eurogentec, Belgium) and 16 nmol/l 18S ribosomal RNA probe (VIC) (Applied Biosystem). Amplification was performed using a 2 min step at 50°C then a 10 min denaturation step at 95°C, followed by 40 cycles of 15 s denaturation at 95°C, 1 min primer annealing polymerization step at 60°C. Thermal cycling and detection of the real-time amplification plot was performed using 7700 Sequence Detection System and analyzed with 'Sequence Detector V.1.6.3' software. All samples were run in duplicate.
The Ct parameter was defined as the fractional cycle number at which the fluorescence passes the fixed threshold. Tera-1 cDNA 10-fold dilution range was used to verify the linearity between Ct and log(RNA concentration) for the HERV-K10 primer/probe system and to determine the PCR efficiency E (data not shown). HERV-K RNA concentration ratio between tested sample (N 0 eval ) and reference sample (N 0 ref ) was calculated by:
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Northern blotting
Ten g of total RNA were resolved on a 1% formaldehyde gel and blotted to a positively charged nylon membrane (Hybond-N+; Amersham). A purified 1126 pb HERV-K10 PCR fragment using primers H2S (5Ј-AGA ACA ATT TTG CCC ATG GTT T-3Ј) and H4R (5Ј-CTG TAC CCC ATC AAT CCA CCA A-3Ј) was labelled with (␣-32 P)dCTP by the random primer DNAlabelling method (Megaprime Labelling System; Amersham). The membrane was hybridized at 42°C in Northern Max buffer (Ambion, USA) overnight and washed in 1 × SCC/0.1% SDS at room temperature for 20 min followed by three washes for 15 min in 0.1 × SCC 0.1 × SDS at 60°C. Control was performed using a purified 238 bp ␤-actin PCR fragment under the same conditions as above except that stringency washes were at 65°C. The blot was exposed for 6 h (␤-actin) or 3 days (HERV-K) to Kodak XAR film at −80°C.
Results
Expression of HERV-K10-like gag gene in leukemia samples and normal PBMCs
Our first step was to investigate HERV-K10-like gag gene expression in PBMCs from normal individuals and from eight leukemia patients with RT-PCR using primers located at the 5Ј part of the gag gene (H1S and H3R) (Figure 1) . A 570 bp amplification product was observed in all eight leukemia samples as well as in normal leukocytes (Figure 2) . The specificity of this product was confirmed after hybridization with the H2S-H4R PCR fragment from the gag region (data not shown).
Because retrotranscription efficiency was equivalent in all samples, as suggested by PBGD pattern, we made the hypothesis that the strong variations of signal intensity between mononuclear cells from leukemia patients and normal PBMCs (except for ALL) might be related to differences in HERV-K trancriptional levels. This, however, could only be confirmed with a quantitative method.
Relative overexpression of HERV-K10-like gag gene in leukemia samples
Transcription levels of HERV-K10-like gag gene were analyzed with real-time quantitative RT-PCR (TaqMan system) using primers and probe located at the same 5Ј part of the gag gene as previously shown (Figure 1 ). This method not only confirmed that HERV-K was expressed in leukemia samples and healthy PBMCs, it also showed that the specific transcript varied in quantity, as demonstrated by the heterogeneous Ct parameters. Differences were not due to the quality of retrotranscription, since the analysis of RNA 18S expression levels confirmed that total cDNA quantity was identical over all the samples tested (Figure 3a and b) . We found an equivalent Ct for PBMCs from five healthy individuals (Ct = 24.5 to 24.9). Therefore, after calculating PCR efficiency (E = 99%, data not shown), we could determine the [HERV-K RNA in tested sample] / [HERV-K RNA in normal PBMCs] concentration ratio.
We noted that the transcriptional activity of HERV-K10-like gag gene was 5-to 8-fold higher in six of the eight leukemia samples analyzed (all three B-CLLs, both AMLs, one of the two CMLs) than in normal PBMCs. In contrast, the ALL and the second CML in blast crisis showed a HERV-K expression similar to that of healthy leukocytes (the 2-fold increase in CML2 was not considered to be significant) ( Table 1) .
HERV-K expression was higher in the teratocarcinoma cell line Tera-1 than in all blood cells, with transcriptional levels 80-fold higher than in normal PBMCs (Table I) . Consequently, we had to assess the transcriptional variations between healthy and leukemia samples with a less sensitive method in order to confirm their real significance.
Relative overexpression of HERV-K10-like sequences in leukemia samples detected by Northern blot
Northern transfer experiments with healthy PBMCs RNA were negative, confirming that HERV-K expression is low in normal PBMCs. In contrast, a strong signal corresponding to a 9 kb transcript (full-length mRNA) was visualized after Tera-1 RNA transfer. This was concordant with the high transcription levels of HERV-K found in these cells. The 5-to 8-fold HERV-K relative overexpression in leukemia samples reached the Northern blot threshold, as shown by the distinct signal for AML2 and the weaker one for all three B-CLLs and CML1 (Figure 4) . 
No significant variation of HERV-K10-like gag gene expression in normal PBMCs after exposure to exogenous agents
We proceeded to test whether such an overexpression could be reproduced in vitro by investigating the effect of different factors on HERV-K expression in normal PBMCs. We used a mitogenic agent, phytohemagglutinin (PHA), cellular stress
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Figure 4
Detection of HERV-K transcripts by Northern blotting. Total RNA was resolved on a 1% formaldehyde gel and transferred to a nylon membrane probed with 32 P-labelled 1126 bp HERV-K PCR fragment H2S-H4R (a) or 238 bp ␤-actin PCR fragment as control (b). generated by gamma irradiation (10 or 25 Gy) and a demethylating substance, 5-azacytidine (AZC). PHA did not affect transcription levels of HERV-K. AZC and gamma irradiation slightly increased HERV-K expression in normal PBMCs, but only by 2.4 (Table 1) .
HERV-K10-like gag gene expression higher in leukemia samples from AMLs than in immature mononuclear cells
In order to further assess our hypothesis that HERV-K expression was associated with leukemic phenotype, we analyzed the expression of the same sequence in mononuclear cells from cord blood (CB), which contains high levels of hematopoietic progenitors and primitive stem cells. We also thought it might be interesting to compare HERV-K transcriptional levels in AML samples and in CB. We therefore determined a HERV-K RNA concentration ratio between tested samples and mononuclear cells from CB using the TaqMan system. HERV-K expression was found to be approximately twice as high in mononuclear cells from CB than in normal PBMCs, but was at least 5-fold lower than in the two leukemia samples analyzed (AML1 and AML2), confirming the relative overexpression of HERV-K in leukemia samples (Table 2) .
Discussion
HERVs constitute a cellular reservoir of possibly pathogenic retroviral genes, which may be involved in carcinogenesis. 1, 6, 7 These retroelements could act as insertion mutagens and activate or inactivate cellular regulation genes. Although the transposition of a HERV element has not yet been detected, other retroelements have been found to be inserted in humans. For example, somatic insertions of LINE-1 elements into intron 2 of the myc gene and the last exon of the adenomatous polyposis coli (APC) gene have been reported in breast carcinoma and colon cancer, respectively. 20, 21 HERVs may also be involved in chromosomal aberrations by acting as sites for recombination events between different chromosomes. Translocation involving THE-7 HERV described in a case of B cell chronic lymphocytic leukemia supports this hypothesis. 22 Finally, transcription of retroviral sequences could give rise to pathogenic retroviral gene products. Envelop proteins of HERVs may participate in tumoral processing by enabling tumor cells to escape immune control on account of their immunosuppressive properties. 2, 23 Possible HERV involvement in tumor development prompted us to investigate HERV expression in leukemic cells. First, we confirmed that the HERV-K10-like gag gene was transcripted in healthy and leukemia samples. Until now and to our knowledge, this was only well-established in chronic myelogenous leukemia. 17 Other studies concerning HERV expression in leukocytes had characterized transcripts with homology to retroviruses after sequencing RT-PCR products obtained from primers corresponding to conserved regions of all retroviral structures 24 or of the HERV-K pol gene. 16 We demonstrated that HERV-K was expressed in PBMCs, as the different methods we used leave very few doubts on the specificity of the transcript we observed.
Next, using real-time quantitative RT-PCR, we found a relative overexpression of HERV-K10-like sequences in PBMCs from six of the eight leukemia samples (all three B-CLLs, both AMLs, one of the two CMLs) compared to healthy PBMCs. The latter seem to be a good reference, as shown by the homogeneous Ct obtained from different normal individualssuggesting that HERV-K expression is probably at the same levels (ie at low levels) among the different normal PBMCs. Relative overexpression in several samples containing tumor cells from different origins suggested that transcriptional variations are related to tumor phenotype rather than to the overrepresentation of a specific lineage. We can also suppose that this overexpression is not due to a population other than leukemic cells, as the latter probably constitute the great majority of cells in most of our samples after Ficoll density gradient separation. Therefore, we suggest that transcriptional activity of HERV-K10-like gag gene is approximately 5-to 10-fold higher in leukemic cells from six of the eight analyzed cases than in healthy PBMCs. This relative overexpression reaches the Northern blot threshold. In addition, immature CB cells do not show a significant overexpression of HERV-K in contrast with AML samples, supporting the idea that this overexpression might be specific to leukemic cells. Nevertheless, the hypothesis that malignant leukocytes may be upregulated in expression of HERV-K10-like sequences should be investigated in greater detail using purified cell populations. HERVs may be inducible by exogenous agents such as Xirradiation, inhibitors of protein synthesis, inflammatory cytokines or steroids. 25 In fact these different factors often correspond to conditions that also induce stress responses. 1 In order to determine whether HERV-K relative overexpression in leukemia samples is simply related to cellular stress or to mitogenic characteristics, we investigated the effect of gamma irradiation and treatment by PHA on HERV-K transcription in healthy PBMCs. PHA did not affect transcription levels of HERV-K in normal PBMCs. Gamma irradiation slightly increased its expression, but the greatest difference with untreated PBMCs, observed 3 h after 10 Gy gamma irradiation, did not exceed 2.4-fold, which can be considered as not significant. These observations also support the hypothesis that HERV-K relative overexpression might be specifically associated with tumor characteristics of leukemic cells.
Studies have reported that HERV-K sequences, as other retroelements, are repressed in normal cells through the methylation of CpG dinucleotides. [8] [9] [10] In this context, it is noteworthy that methylation imbalance plays an important role in tumor processing. 26, 27 Moreover, general genomic hypomethylation was described in chronic lymphocytic leukemia. 28 Therefore, we investigated whether hypomethylation of HERV-K10-like sequences in leukemic cells could be involved in this overexpression. However, when we treated healthy PBMCs with a demethylating substance, 5-azacytidine (5-AZC), we found only a slight, non-significant overexpression of HERV-K10-like sequences (2.4-fold). Two hypotheses can be inferred from this result: either the HERV-K relative overexpression in leukemic cells is not due (or only partially due) to hypomethylation, or 5-AZC is not effective in hypomethylating the gag gene and adjacent 5ЈLTR in normal PBMCs. To further assess our hypothesis of a relationship between HERV-K overexpression and hypomethylation of this sequence in leukemic cells, we are now investigating HERV-K methylation status in normal PBMCs (before and after exposure to 5-AZC) and in leukemia samples with Southern blot analysis.
In this study, we found a relative overexpression of the endogenous retrovirus HERV-K in the blood cells from six of the eight leukemia samples analyzed. This overexpression might be specifically related to tumor development and is therefore worth being investigated further. After considering the different mechanisms potentially involving HERVs in car-cinogenesis, we suggest that overexpression of HERV may participate in leukemic processing. Furthermore, members of HERV-K display complete open reading frames, in particular for a Gag polyprotein. This protein has already been described in germ cell tumors where it correlates with the presence of specific antibodies in patients' sera. 13, 14 The relative overexpression of HERV-K10-like sequences we report here is concordant with the description by Denner et al 19 of an antibody response against HERV-K peptides in leukemic patients. Therefore, it is important in the near future to determine whether the relative overexpression of HERV-K in leukemia samples is associated with synthesis of a Gag protein.
